Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms.

Tissue antigens - 1 Apr 2007

Cabrera T, Maleno I, Collado A, Lopez Nevot M A, Tait B D, Garrido F

Abstract excerpt

The application of peptide-based immunotherapy in the treatment of cancer has known limitations in patients with loss or downregulation of human leukocyte antigen (HLA) class I expression on tumor cells. These alterations diminish the ability of cancer cells to present tumor peptides to T cells and therefore lead to failure of peptide-based cancer vaccination. Abnormal expression of HLA class I molecules in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histocompatibility Antigens Class I
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Loss of Heterozygosity

Share to Microsatellite Repeats

Share to Mutation

Share to Neoplasms

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 17445216
DOI: 10.1111/j.1399-0039.2006.00777.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms.PMID 17445216Read ↗

Role of altered expression of HLA class I molecules in cancer progression.Semantic proximity Read ↗

The HLA crossroad in tumor immunology.Semantic proximity Read ↗

Deregulation of HLA-I in cancer and its central importance for immunotherapySemantic proximity Read ↗

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implicationsSemantic proximity Read ↗

Targeting HLA class I expression to increase tumor immunogenicitySemantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

Different mechanisms can lead to the same altered HLA class I phenotype in tumors.Semantic proximity Read ↗

Altered MHC class I antigens in tumors.Semantic proximity Read ↗

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.Semantic proximity Read ↗

The biological consequences of altered MHC class I expression in tumours.Semantic proximity Read ↗

Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyondSemantic proximity Read ↗

Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.